@Bigdaddio
My summary would be that the clinical trial is designed in such a way (based on the results of the phase 2 trial) that allows for the maximum probability for success.
The key statistic I would be keeping an eye out for is left ventricular ejection fraction (LVEF). If it's increased significantly in the MPC-150-IM group, then this treatment would be a massive home run.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
0.025(1.47%) |
Mkt cap ! $2.207B | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.73 | $1.64 | $4.189M | 2.480M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31201 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 59276 | 6 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |